Pretreatment Nutritional Status in Combination with Inflammation Affects Chemotherapy Interruption in Women with Ovarian, Fallopian Tube, and Peritoneal Cancer

Nutrients. 2022 Dec 6;14(23):5183. doi: 10.3390/nu14235183.

Abstract

Background: Discontinuing chemotherapy worsens cancer prognosis. This study aimed to investigate the relationship between nutritional status at the start of chemotherapy and chemotherapy discontinuation in patients with ovarian, fallopian tube, and primary peritoneal cancer.

Methods: This was a retrospective cohort study. One hundred and forty-six patients to whom weekly paclitaxel and carboplatin were administered as postoperative chemotherapy were included. Six courses in 21-day cycles were defined as complete treatment. As nutritional indicators, body mass index, weight change rate, serum albumin, total lymphocyte count, prognostic nutritional index, and C-reactive protein-to-albumin ratio (CAR) were compared between complete and incomplete treatment groups. Patients were divided into two groups according to CAR. The number of chemotherapy cycles was compared between these two groups. A Cox proportional hazard model was used for covariate adjustment.

Results: Several indicators differed between complete and incomplete treatment groups, and among the indicators, CAR had the highest discriminatory ability. The number of chemotherapy cycles was shorter in the high CAR group than in the low CAR group. A high CAR was associated with chemotherapy interruption even after adjusting for covariates.

Conclusion: Based on CAR, nutritional status before chemotherapy is suggested to be associated with the risk of chemotherapy discontinuation.

Keywords: chemotherapy interruption; fallopian tube cancer; nutritional status; ovarian cancer; peritoneal cancer.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Fallopian Tube Neoplasms* / drug therapy
  • Fallopian Tube Neoplasms* / etiology
  • Fallopian Tube Neoplasms* / surgery
  • Fallopian Tubes
  • Female
  • Humans
  • Nutritional Status
  • Ovarian Neoplasms* / drug therapy
  • Peritoneal Neoplasms* / drug therapy
  • Peritoneal Neoplasms* / surgery
  • Retrospective Studies

Grants and funding

This research received no external funding.